- Shares of Geron (GERN) are up 9% in premarket trading.
- Behind the move looks to be an article outlining a Mayo Clinic study which says imetelstat "has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis."
- The study's lead author calls the results "early but promising."
- Amusingly, the article appears to have been posted ahead of its scheduled release from embargo.
- Full article is here
at Zacks.com (Nov 17, 2014)